Immunic, Inc.
IMUX · Nasdaq · United States
Share price · IMUX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when IMUX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 13 Oct 2026-13.3%
Nothing announced by IMUX that day or the session before.
- 2 Oct 2026-7.9%
Nothing announced by IMUX that day or the session before.
- 23 Sep 2026-13.6%
Nothing announced by IMUX that day or the session before.
- 3 Sep 2026-10.4%
- 1 Sep 2026-7.7%
Nothing announced by IMUX that day or the session before.
- 11 Aug 2026+9.8%
- 27 Apr 2026+1034.0%
Nothing announced by IMUX that day or the session before.
- 13 Mar 2026-14.6%
Nothing announced by IMUX that day or the session before.
- 11 Mar 2026+12.4%
- 19 Feb 2026+11.1%
Nothing announced by IMUX that day or the session before.
Share of unusual movement by asset
For each asset, the share of IMUX's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Dihydroorotate dehydrogenase (DHODH) | Multiple Sclerosis | |
| Preclinical / Unstaged | SIRT6Small molecule | Celiac Disease |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (17)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $24M | $132M | $42M-$28M operating cash flow | report ↗ |
View 16 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $26M | $155M | $34M-$31M operating cash flow | report ↗ |
| 2026-Q1 | — | $26M | $187M | $33M-$17M operating cash flow | report ↗ |
| 2025-Q3 | — | $20M | $35M | $26M-$20M operating cash flow | report ↗ |
| 2025-Q2 | — | $21M | $55M | $27M-$25M operating cash flow | report ↗ |
| 2025-Q1 | — | $22M | $14M | $25M-$22M operating cash flow | report ↗ |
| 2024-Q3 | — | $21M | $59M | $24M-$21M operating cash flow | report ↗ |
| 2024-Q2 | — | $18M | $80M | $21M-$17M operating cash flow | report ↗ |
| 2024-Q1 | — | $19M | $97M | $30M-$24M operating cash flow | report ↗ |
| 2023-Q3 | — | $20M | $60M+ $0 short-term inv. | $23M-$17M operating cash flow | report ↗ |
| 2023-Q2 | — | $21M | $77M+ $0 short-term inv. | $24M-$20M operating cash flow | report ↗ |
| 2023-Q1 | — | $23M | $93M+ $4.3M short-term inv. | $25M-$20M operating cash flow | report ↗ |
| 2022-Q3 | — | $17M | $73M | $21M-$14M operating cash flow | report ↗ |
| 2022-Q2 | — | $17M | $88M | $22M-$16M operating cash flow | report ↗ |
| 2022-Q1 | — | $17M | $96M | $21M-$21M operating cash flow | report ↗ |
| 2021-Q4 | — | — | $87M+ $0 short-term inv. | $21M-$24M operating cash flow | report ↗ |
| 2021-Q3 | — | $15M | $110M | $19M-$18M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $82M | $15M | $24M-$86M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $80M | $36M | $25M-$85M operating cash flow | report ↗ |
| 2023-FY | — | $83M | $47M+ $0 short-term inv. | $23M-$71M operating cash flow | report ↗ |
| 2022-FY | — | $71M | $107M+ $9.6M short-term inv. | $30M-$65M operating cash flow | report ↗ |
| 2021-FY | — | $61M | $87M+ $0 short-term inv. | $23M-$83M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-16 | BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND L P; BVF I GP LLC; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF GP HOLDINGS LLC; BVF INC/IL; LAMPERT MARK N · director; director; director; director; director; director; director; director; director; director | Award / grant (derivative) | 25,370 | — | — | Form 4 |
| 2026-09-16 | Nagel Robert Thorvald · director | Award / grant (derivative) | 25,370 | — | — | Form 4 |
| 2026-08-06 | Ridloff Elena · director | Award / grant (derivative) | 50,740 | — | — | Form 4 |
| 2026-07-05 | Congleton Jon · director | Award / grant (derivative) | 25,370 | — | — | Form 4 |
| 2026-07-05 | Neermann Joerg · director | Award / grant (derivative) | 25,370 | — | — | Form 4 |
| 2026-07-05 | PHILLIPS BARCLAY A · director | Award / grant (derivative) | 25,370 | — | — | Form 4 |
| 2026-07-05 | Rudick Richard Alan · director | Award / grant (derivative) | 25,370 | — | — | Form 4 |
| 2026-07-05 | Skerjanec Simona · director | Award / grant (derivative) | 25,370 | — | — | Form 4 |